Business Context and Reporting Period
This Form 8-K Current Report was filed by Aclaris Therapeutics, Inc. on January 25, 2017. The filing discloses the appointment of a new director and related compensatory arrangements.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes.
Material Changes
On January 25, 2017, the Board of Directors appointed Andrew Powell as a Class II director, effective immediately. His term will expire at the 2017 annual meeting of stockholders. Mr. Powell replaced Christopher Molineaux on the Audit Committee and was appointed to the Nominating and Corporate Governance Committee.
Compensation and Governance Details
- Stock Options: Mr. Powell was granted a nonqualified stock option to purchase 16,000 shares of common stock. The exercise price equals the closing price on the grant date. The option vests in 36 equal monthly installments contingent on continuous service.
- Annual Retainers:
- Director service: $35,000
- Audit Committee service: $7,500
- Nominating and Corporate Governance Committee service: $4,000
- Future Grants: At each subsequent annual stockholder meeting, Mr. Powell is entitled to an additional option for 8,000 shares, vesting over 12 months.
- Background: Mr. Powell previously served as Senior Vice President and General Counsel at Medivation, Inc., InterMune, Inc., and ImClone Systems, Inc.
Investor Verification Checklist
- Verify the closing stock price on January 25, 2017, to determine the exercise price of the initial 16,000 share option grant.
- Confirm the total annual cash compensation ($46,500) against the company's standard director compensation policy.
- Review the press release dated January 26, 2017 (Exhibit 99.1) for additional context on the appointment.
- Monitor the 2017 annual meeting of stockholders for the expiration of Mr. Powell's initial director term.